Plain Language Summary Clause Samples
A Plain Language Summary clause provides a simplified, easy-to-understand overview of the key terms and provisions of a contract. This summary is typically written in straightforward language, avoiding legal jargon, and highlights the main obligations, rights, and responsibilities of the parties involved. Its core practical function is to ensure that all parties, regardless of legal expertise, can clearly understand the essential elements of the agreement, thereby reducing the risk of misunderstandings or disputes.
Plain Language Summary. A written statement describing the Financial Assistance Policy in language that is clear, concise, and easy to understand with the aim that as much of it as practicable (given the topic and substance of the document) be drafted at a fifth- grade reading level.
Plain Language Summary. You can refuse to provide personal information, use an alternative name or remain anonymous when seeking treatment unless there is a legal or practical reason why this is not possible. If you choose this option you must pay the full fee. Access to client information PLAIN LANGUAGE SUMMARY: You are entitled to access your personal information kept on file, in line with privacy and freedom of information laws. Disclosure of personal information
Plain Language Summary. Project Objectives (75 word max), Project Introduction/Rationale (75 word max, Provide background information on the project and explain why the topic of the project is important.), Research Approach (100 word max, Describe the research approach for this project.), Key findings, Conclusions, and Benefits to Subscribers/industry (250 word max, Describe the results/ findings of the research. Include how the finding impact Subscribers and advance the reuse/desalination industry.
Plain Language Summary. Your information is securely stored. It will only be accessible to your treating psychologist and practice staff (as necessary). You can obtain information from the clinic about how to lodge a complaint if you are not happy with the way in which your personal information is handled. Consequence of not providing personal information
Plain Language Summary. For a drug to be approved, the European Medicines Agency (EMA) studies its benefits and risks. If the drug has larger benefits than risks, it will be approved in the European Union. These studies are known as benefit-risk assessments. However, the drug will not be available immediately on the European markets. It will be up to the member states’ national health authorities to decide whether they will pay for it. These national health authorities are also called health technology assessment agencies. To decide, they will study whether the drug is of additional benefit in comparison with alternative treatments available in the country. These comparisons are known as relative effectiveness assessments. It is unknown whether European and national health authorities agree when discussing what is an alternative treatment. It is also unclear if, for a given drug, there is a relation between the absence of alternative treatments and the determination of its relative effectiveness. This study tried to clarify this. Therefore, we searched for the files in which the relative effectiveness had been studied in six different national health agencies’ websites: AEMPS (Spain), AIFA (Italy), HAS (France), IQWiG/G-BA (Germany), NICE (England and Wales), and ZIN (the Netherlands). We only included drugs that were approved by the EMA between 2019 and 2021, and we excluded vaccines and diagnostic tools. Afterward, we examined the agreement between EMA and national health authorities on the availability of alternative treatments and the relationship between the absence of alternative treatments and the study of a drug’s additional benefit. Overall, for the 97 drugs that matched our criteria, there were 460 studies of relative effectiveness for the six national health agencies. There was a high agreement between the EMA and national health agencies on the presence of alternative treatments. Our study showed that when there was no alternative treatment for a drug, it was almost 2 times more likely to be considered of additional benefit by the national health authorities. In conclusion, there were differences in how the European and the national health agencies see alternative treatments and in the local availability of drugs. When there was no alternative, it was more likely for a drug to be considered of additional benefit. As one of the next steps in European collaboration between national health authorities will be the joint assessment of a drug’s relative effectiveness, the d...